Carrera Capital Advisors Lowers Position in Stryker Corporation $SYK

by · The Cerbat Gem

Carrera Capital Advisors cut its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 68.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,381 shares of the medical technology company’s stock after selling 5,260 shares during the quarter. Carrera Capital Advisors’ holdings in Stryker were worth $752,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the stock. Sankala Group LLC purchased a new position in Stryker in the 4th quarter worth $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker in the third quarter worth about $27,000. Godfrey Financial Associates Inc. bought a new stake in shares of Stryker in the 4th quarter valued at about $26,000. Atlas Capital Advisors Inc. bought a new stake in shares of Stryker in the 4th quarter valued at about $27,000. Finally, Strive Asset Management LLC purchased a new stake in Stryker during the 3rd quarter valued at about $30,000. Institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 4.60% of the company’s stock.

Stryker Stock Down 0.7%

NYSE:SYK opened at $338.80 on Friday. The firm’s 50-day moving average price is $324.61 and its 200-day moving average price is $333.57. The company has a market capitalization of $129.95 billion, a PE ratio of 35.11, a P/E/G ratio of 2.17 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86.

Stryker (NYSE:SYK – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same period last year, the company posted $3.13 EPS. Stryker’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts predict that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.

Analyst Ratings Changes

SYK has been the topic of a number of analyst reports. Evercore set a $350.00 price target on Stryker in a research note on Monday, July 6th. Robert W. Baird set a $385.00 price objective on Stryker in a research note on Friday, May 1st. Citigroup restated a “buy” rating on shares of Stryker in a report on Thursday. Truist Financial lifted their target price on shares of Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a research note on Friday, July 31st. Finally, Piper Sandler dropped their price target on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Read Our Latest Research Report on SYK

Stryker Company Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Read More